BMS and Eisai agree antibody-drug conjugate commercialisation deal
By 
Phillip Broadwith2021-06-22T09:50:00
Companies will jointly develop cancer treatment, with BMS paying up to $3 billion for shared rights
Bristol Myers Squibb (BMS) and Eisai have agreed a deal to co-develop Eisai’s antibody-drug conjugate cancer treatment MORAb-202. BMS will pay $650 million up front, including $200 million earmarked for R&D. Eisai will be eligible to receive up to $2.45 billion in further performance-related payments.